Neuland Laboratories Ltd.
NEULANDLAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹9,521.13.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- ✓Low debt (D/E < 0.5)0.16x
- ✕Positive free cash flow
- ✓Revenue growth > 10%136%
- ✓Earnings growing664%
- ✕Net margin ≥ 10%2.3%
- ✕Current ratio > 1.51.42
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 13.73
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 13.73.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Earnings growing (664% YoY).
- •Revenue growing (136% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~30% above our estimated fair value.
About Neuland Laboratories Ltd.
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.